Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:3099-3108
Published online before print June 2, 2008, doi: 10.1161/CIRCULATIONAHA.108.767673
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
117/24/3099    most recent
CIRCULATIONAHA.108.767673v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oshima, Y.
Right arrow Articles by Walsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oshima, Y.
Right arrow Articles by Walsh, K.
Related Collections
Right arrow Apoptosis
Right arrow Cell signalling/signal transduction
Right arrow Growth factors/cytokines
Right arrow Physiological and pathological control of gene expression
Right arrowRelated Article

(Circulation. 2008;117:3099-3108.)
© 2008 American Heart Association, Inc.


Molecular Cardiology

Follistatin-Like 1 Is an Akt-Regulated Cardioprotective Factor That Is Secreted by the Heart

Yuichi Oshima, MD, PhD; Noriyuki Ouchi, MD, PhD; Kaori Sato, MD, PhD; Yasuhiro Izumiya, MD, PhD; David R. Pimentel, MD; Kenneth Walsh, PhD

From Molecular Cardiology, Whitaker Cardiovascular Institute (Y.O., N.O., K.S., Y.I., K.W.), and the Myocardial Biology Unit (D.R.P.), Boston University Medical Campus, Boston, Mass.

Correspondence to Kenneth Walsh, PhD, Molecular Cardiology/Whitaker Cardiovascular Institute, Boston University Medical School, 700 Albany St, W611, Boston, MA 02118. E-mail kxwalsh{at}bu.edu

Received January 18, 2008; accepted April 9, 2008.

Background— The Akt protein kinase is an important mediator of cardiac myocyte growth and survival. To identify factors with novel therapeutic applications in cardiac diseases, we focused on the identification of factors secreted from Akt1-activated cells that have cardioprotective effects through autocrine/paracrine mechanisms.

Methods and Results— Using an inducible Akt1 transgenic mouse model, we have found that follistatin-like 1 (Fstl1) protein and transcript expression are increased 4.0- and 2.0-fold, respectively, by Akt activation in the heart (P<0.05). Fstl1 transcript was also upregulated in response to myocardial stresses including transverse aortic constriction, ischemia/reperfusion injury, and myocardial infarction. Adenovirus-mediated overexpression of Fstl1 protected cultured neonatal rat ventricular myocytes from hypoxia/reoxygenation-induced apoptosis (P<0.01), and this protective effect was dependent on the upregulation of both Akt and ERK activities. Conversely, knockdown of Fstl1 in cardiac myocytes decreased basal Akt signaling and increased the frequency of apoptotic death in vitro (P<0.01). The intravenous administration of an adenoviral encoding Fstl1 to mice resulted in a 66.0% reduction in myocardial infarct size after ischemia/reperfusion injury that was accompanied by a 70.9% reduction in apoptosis in the heart (P<0.01).

Conclusions— These results indicate that Fstl1 is a cardiac-secreted factor that functions as an antiapoptotic protein. Fstl1 could play a role in myocardial maintenance and repair in response to harmful stimuli.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 3055-3056. [Extract] [Full Text]



This article has been cited by other articles:


Home page
CirculationHome page
Y. Oshima, N. Ouchi, M. Shimano, D. R. Pimentel, K. N. Papanicolaou, K. D. Panse, K. Tsuchida, E. Lara-Pezzi, S.-J. Lee, and K. Walsh
Activin A and Follistatin-Like 3 Determine the Susceptibility of Heart to Ischemic Injury
Circulation, October 20, 2009; 120(16): 1606 - 1615.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. Widera, R. Horn-Wichmann, T. Kempf, K. Bethmann, B. Fiedler, S. Sharma, R. Lichtinghagen, H. Leitolf, B. Ivandic, H. A. Katus, et al.
Circulating Concentrations of Follistatin-Like 1 in Healthy Individuals and Patients with Acute Coronary Syndrome as Assessed by an Immunoluminometric Sandwich Assay
Clin. Chem., October 1, 2009; 55(10): 1794 - 1800.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
D. Lachance, E. Plante, A.-A. Bouchard-Thomassin, S. Champetier, E. Roussel, M.-C. Drolet, M. Arsenault, and J. Couet
Moderate Exercise Training Improves Survival and Ventricular Remodeling in an Animal Model of Left Ventricular Volume Overload
Circ Heart Fail, September 1, 2009; 2(5): 437 - 445.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. F. Keaney Jr and D. R. Weaver
Vascular Rhythms and Adaptation: Do Your Arteries Know What Time It Is?
Circulation, March 24, 2009; 119(11): 1463 - 1466.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Ouchi, Y. Oshima, K. Ohashi, A. Higuchi, C. Ikegami, Y. Izumiya, and K. Walsh
Follistatin-like 1, a Secreted Muscle Protein, Promotes Endothelial Cell Function and Revascularization in Ischemic Tissue through a Nitric-oxide Synthase-dependent Mechanism
J. Biol. Chem., November 21, 2008; 283(47): 32802 - 32811.
[Abstract] [Full Text] [PDF]